These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 3096778)

  • 1. Purification of epidermal plasminogen activator inhibitor.
    Hibino T; Izaki S; Izaki M
    FEBS Lett; 1986 Nov; 208(2):273-7. PubMed ID: 3096778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secretion of plasminogen activator inhibitor by cultured human epidermal cells.
    Hashimoto K; Nishioka K; Katayama I; Yoshikawa K
    Br J Dermatol; 1986 Aug; 115(2):133-8. PubMed ID: 3091060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amiloride selectively inhibits the urokinase-type plasminogen activator.
    Vassalli JD; Belin D
    FEBS Lett; 1987 Apr; 214(1):187-91. PubMed ID: 3106085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and partial characterization of a specific plasminogen activator inhibitor in human chondrocyte cultures.
    Yamada H; Stephens RW; Nakagawa T; McNicol D
    J Biochem; 1988 Dec; 104(6):960-7. PubMed ID: 3149640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells.
    Coleman PL; Patel PD; Cwikel BJ; Rafferty UM; Sznycer-Laszuk R; Gelehrter TD
    J Biol Chem; 1986 Mar; 261(9):4352-7. PubMed ID: 2936742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purification and characterization of an inhibitor of plasminogen activator released by rat mammary adenocarcinoma cells.
    Grant AJ; Ramshaw IA; Badenoch-Jones P; Eichner RD; Hunt NH
    Eur J Biochem; 1986 Feb; 154(3):635-41. PubMed ID: 3081343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cyclopeptidic suicide substrate preferentially inactivates urokinase-type plasminogen activator.
    Reboud-Ravaux M; Vilain AC; Boggetto N; Maillard J; Favreau C; Xie J; Mazaleyrat JP; Wakselman M
    Biochem Biophys Res Commun; 1991 Jul; 178(1):352-9. PubMed ID: 1829886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An inhibitor of plasminogen activation from human placenta. Purification and characterization.
    Wun TC; Reich E
    J Biol Chem; 1987 Mar; 262(8):3646-53. PubMed ID: 3102492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microplate immunocapture assay for plasminogen activators and their specific inhibitors.
    Stephens R; Leung KC; Pöllänen J; Salonen EM; Vaheri A
    J Immunol Methods; 1987 Dec; 105(2):245-51. PubMed ID: 3121752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The irreversible inhibition of urokinase, kidney-cell plasminogen activator, plasmin and beta-trypsin by 1-(N-6-amino-n-hexyl)carbamoylimidazole.
    Walker B; Elmore DT
    Biochem J; 1984 Jul; 221(1):277-80. PubMed ID: 6235806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly-D-lysine dependent inactivation of tissue plasminogen activator by a class PAI-2 inhibitor (minactivin).
    Leung KC; Byatt JA; Stephens RW
    Thromb Res; 1987 Jun; 46(6):767-77. PubMed ID: 3114909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The plasma inhibitors of plasminogen activator, studied by a zymographic technique.
    Booth NA; Anderson JA; Bennett B
    Thromb Res; 1985 May; 38(3):261-7. PubMed ID: 3161209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.
    Lawrence D; Strandberg L; Grundström T; Ny T
    Eur J Biochem; 1989 Dec; 186(3):523-33. PubMed ID: 2514093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endotoxin induction of an inhibitor of plasminogen activator in bovine pulmonary artery endothelial cells.
    Crutchley DJ; Conanan LB
    J Biol Chem; 1986 Jan; 261(1):154-9. PubMed ID: 3079753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site.
    Keijer J; Linders M; Wegman JJ; Ehrlich HJ; Mertens K; Pannekoek H
    Blood; 1991 Sep; 78(5):1254-61. PubMed ID: 1715220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.
    Thorsen S; Philips M; Selmer J; Lecander I; Astedt B
    Eur J Biochem; 1988 Jul; 175(1):33-9. PubMed ID: 3136015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
    Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
    Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.
    Andreasen PA; Nielsen LS; Kristensen P; Grøndahl-Hansen J; Skriver L; Danø K
    J Biol Chem; 1986 Jun; 261(17):7644-51. PubMed ID: 3086313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purification of a plasminogen activator inhibitor indistinguishable from alpha1-antitrypsin and an urokinase inhibitor in pregnancy plasma.
    Clemmensen I; Thorsen S; Müllertz S
    Haemostasis; 1976; 5(4):218-30. PubMed ID: 826461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial purification and characterization of epidermal plasminogen activator and their inhibitor.
    Nakagawa M; Fukuyama K; Epstein WL; Hara A; Sawada H
    Chem Pharm Bull (Tokyo); 1989 Jul; 37(7):1859-63. PubMed ID: 2509088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.